跳至主要内容
临床试验/NCT02188953
NCT02188953已完成2 期

Evaluation of the Effectiveness, Acceptability, and Palatability of Air Classified Calcium Silicate (ACCS100) Clay to Reduce Aflatoxin Exposure in a High-risk Community in Kenya

Kenya Medical Research Institute1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
1
主要终点
Change from baseline of urine aflatoxin M1 levels

研究概览

简要总结

The purpose of this study is to pilot test the effectiveness, acceptability, and palatability of ACCS100 in a high-risk Kenyan population.

详细描述

Aflatoxins are harmful by-products of the molds Aspergillus flavus and A. parasiticus and are major contaminants of agricultural produce such as maize. Acute aflatoxin exposure (i.e., aflatoxicosis) can lead to jaundice, vomiting, abdominal pain, and liver failure, with documented fatality rates as high as 40%. Kenya experiences extreme aflatoxin exposure and fatal, recurring aflatoxicosis outbreaks. Numerous clinical trials have found heat processed calcium dioctahedral smectite clay [i.e., Air Classified Calcium Silicate (ACCS100)] to be safe and effective in binding to aflatoxin to decrease bioavailability and subsequently reduce toxin-induced effects. The investigators propose to pilot test the effectiveness, acceptability, and palatability of ACCS100 in a high-risk Kenyan population. If successful, ACCS100 could be scaled-up for use in Kenya to prevent aflatoxin-associated mortality during high-risk periods. To accomplish this objective, the investigators will recruit fifty health adults into a crossover study. Each participant will spend one week consuming ACCS100 and one week consuming a calcium carbonate placebo. Daily first morning void urine samples will monitor effectiveness in reducing aflatoxin bioavailability, and periodic questionnaires will assess acceptance and palatability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult ≥18 years of age
  • Consumes corn- and/or peanut-derived foods at least four times per week
  • No plans to travel away from the household for more than one day in the next month

排除标准

  • Women who may be pregnant
  • History of medical illnesses
  • Presence of protein or glucose in urine using chemstrip
  • Does not provide informed consent

研究组 & 干预措施

ACCS100

Experimental

Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.

干预措施: ACCS100 (Drug)

Calcium carbonate

Placebo Comparator

Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.

干预措施: Calcium carbonate placebo (Drug)

结局指标

主要结局

Change from baseline of urine aflatoxin M1 levels

时间窗: Daily during each study arm

Urine samples will be collected at baseline (Day 0) and daily for seven days during Arm 1 (Days 1-7). Urine samples will also be collected at baseline (Day 13) and daily for seven days during Arm 2 (Days 13-19).

次要结局

  • Daily diary and adverse event reporting form(Daily during arm 1 (Days 2-8) and arm 2 (Days 14-20))
  • Serum aflatoxin B1-lysine adduct levels(Baseline of Arm 1 (Day 0) and end of arm 2 (Day 20))
  • Palatability questionnaire(End of arm 1 (Day 8) and end of arm 2 (Day 20))
  • Acceptability questionnaire(End of arm 2 (Day 20))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. John Vulule

Director, Center for Global Health Research

Kenya Medical Research Institute

研究点 (1)

Loading locations...

相似试验